Adelaida Lacasta
University of the Basque Country
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adelaida Lacasta.
World Journal of Gastroenterology | 2011
José M. Enríquez-Navascués; Nerea Borda; Aintzane Lizerazu; Carlos Placer; José Luis Elósegui; Juan Pablo Ciria; Adelaida Lacasta; Luis Bujanda
Improvements in surgery and the application of combined approaches to fight rectal cancer have succeeded in reducing the local recurrence (LR) rate and when there is LR it tends to appear later and less often in isolation. Moreover, a subtle change in the distribution of LRs with respect to the pelvis has been observed. In general terms, prior to total mesorectal excision the most common LRs were central types (perianastomotic and anterior) while lateral and posterior forms (presacral) have become more common since the growth in the use of combined treatments. No differences have been reported in the current pattern of LRs as a function of the type of approach used, that is, neo-adjuvant therapies (short-term or long-course radiotherapy, or chemoradiotherapy versus extended lymphadenectomy, though there is a trend towards posterior or presacral LR in patients in the Western world and lateral LR in Asia. Nevertheless, both may arise from the same mechanism. Moreover, as well as the mode of treatment, the type of LR is related to the height of the initial tumor. Nowadays most LRs are related to the advanced nature of the disease. Involvement of the circumferential radial margin and spillage of residual tumor cells from lymphatic leakage in the pelvic side wall are two plausible mechanisms for the genesis of LR. The patterns of pelvic recurrence itself (pelvic subsites) also have important implications for prognosis and are related to the potential success of salvage curative approach. The re-operability for cure and prognosis are generally better for anastomotic and anterior types than for presacral and lateral recurrences. Overall survival after LR diagnosis is lower with radio or chemoradiotherapy plus optimal surgery approaches, compared to optimal surgery alone.
Journal of Hepatology | 2016
Maite Merino-Azpitarte; Elisa Lozano; M.J. Perugorria; Aitor Esparza-Baquer; Oihane Erice; Alvaro Santos-Laso; Colm J. O'Rourke; Jesper B. Andersen; R. Jiménez-Agüero; Adelaida Lacasta; Mauro D'Amato; Oscar Briz; Nidhi Jalan-Sakrikar; Robert C. Huebert; Kristen M. Thelen; Sergio A. Gradilone; Ana M. Aransay; José Luis Lavin; M.G. Fernandez-Barrena; Ander Matheu; Marco Marzioni; Gregory J. Gores; Luis Bujanda; Jose J.G. Marin; Jesus M. Banales
BACKGROUND & AIMS Cholangiocarcinoma (CCA) is a biliary malignancy linked to genetic and epigenetic abnormalities, such as hypermethylation of SOX17 promoter. Here, the role of SOX17 in cholangiocyte differentiation and cholangiocarcinogenesis was studied. METHODS SOX17 expression/function was evaluated along the differentiation of human induced pluripotent stem cells (iPSC) into cholangiocytes, in the dedifferentiation process of normal human cholangiocytes (NHC) in culture and in cholangiocarcinogenesis. Lentiviruses for SOX17 overexpression or knockdown were used. Gene expression and DNA methylation profiling were performed. RESULTS SOX17 expression is induced in the last stage of cholangiocyte differentiation from iPSC and regulates the acquisition of biliary markers. SOX17 becomes downregulated in NHC undergoing dedifferentiation; experimental SOX17 knockdown in differentiated NHC downregulated biliary markers and promoted baseline and Wnt-dependent proliferation. SOX17 expression is lower in human CCA than in healthy tissue, which correlates with worse survival after tumor resection. In CCA cells, SOX17 overexpression decreased their tumorigenic capacity in murine xenograft models, which was related to increased oxidative stress and apoptosis. In contrast, SOX17 overexpression in NHC did not affect their survival but inhibited their baseline proliferation. In CCA cells, SOX17 inhibited migration, anchorage-independent growth and Wnt/β-catenin-dependent proliferation, and restored the expression of biliary markers and primary cilium length. In human CCA, SOX17 promoter was found hypermethylated and its expression inversely correlates with the methylation grade. In NHC, Wnt3a decreased SOX17 expression in a DNMT-dependent manner, whereas in CCA, DNMT1 inhibition or silencing upregulated SOX17. CONCLUSIONS SOX17 regulates the differentiation and maintenance of the biliary phenotype and functions as a tumor suppressor for CCA, being a potential prognostic marker and a promising therapeutic target. LAY SUMMARY Understanding the molecular mechanisms involved in the pathogenesis of CCA is key in finding new valuable diagnostic and prognostic biomarkers, as well as therapeutic targets. This study provides evidence that SOX17 regulates the differentiation and maintenance of the biliary phenotype, and its downregulation promotes their tumorigenic transformation. SOX17 acts as a tumor suppressor in CCA and its genetic, molecular and/or pharmacological restoration may represent a new promising therapeutic strategy. Moreover, SOX17 expression correlates with the outcome of patients after tumor resection, being a potential prognostic biomarker.
Medicina Clinica | 2009
Luis Bujanda; Inés Gil; Cristina Sarasqueta; Elisabeth Hijona; Angel Cosme; José Luis Elorza; José Ignacio Asensio; Santiago Larburu; Adelaida Lacasta; Sara Arevalo; Julián Mínguez
BACKGROUND AND OBJECTIVE The esophageal cancer (EC) is a slightly frequent but serious disease. Our aim is to describe the characteristics of the patients with EC in our Hospital. PATIENTS AND METHOD We included 200 patients consecutively diagnosed and/or treated for CE between between January, 2003 and December, 2007. The location of the tumor was analyzed, the histological type, the proofs realized for to establish the classification, the treatments, the survival and the morbi-mortality of the surgery. RESULTS The endoscopic ultrasonography (EUS) modified the therapeutic strategy in 12% of the patients. The survival to the year, 3 years and 5 years was 48%, 25% and 21%, respectively. 74 (32%) patients were operated, 48 (65%) of them was treated with neoadjuvant chemoradiotherapy. The postsurgical mortality was 8% (6 patients) and the morbidity was 57% (114 patients). In multivariate analysis, after adjustment for traditional risk factors, were the location in the average third ( [HR, hazard ratio]=2.3; confidence interval [IC] of 95%, 1.3-4.1) and not accomplishment of surgery after the chemotherapy and radiotherapy (HR=1.9; IC to 95%, 1.15-3). CONCLUSIONS The diagnosis is realized very later. The EUS has contributed a better therapeutic strategy to our patients. The mortality continues being high.
Journal of Hepatology | 2017
Ander Arbelaiz; M. Azkargorta; Alvaro Santos-Laso; M.J. Perugorria; Oihane Erice; E. Gonzalez; A. Lapitz; L. Izquierdo; P. Olaizola; P.Y. Lee; A. Arregi; R. Jiménez-Agüero; Adelaida Lacasta; C. Ibarra; A. Sánchez-Campos; J.P. Jimeno; Marcin Krawczyk; Frank Lammert; Marco Marzioni; R. Macias; J.J. Marín; Tushar Patel; Gregory J. Gores; I. Martinez; F. Elortza; J.M. Falcón-Pérez; Luis Bujanda; Jesus M. Banales
Journal of Hepatology | 2018
Ander Arbelaiz; Ainhoa Lapitz; Marcin Krawczyk; Alvaro Santos-Laso; José Luis Lavin; M.J. Perugorria; R. Jiménez-Agüero; Adelaida Lacasta; C. Ibarra; A. Sanchez-Campos; Juan P. Jimeno; Esperanza Gonzalez; Frank Lammert; Marco Marzioni; Rocio I.R. Macias; Jose J.G. Marin; Tom H. Karlsen; J. Falcon-Perez; A. María Aransay; Luis Bujanda; Jesus M. Banales
Journal of Hepatology | 2018
Jesus M. Banales; Mercedes Iñarrairaegui; Ander Arbelaiz; Piotr Milkiewicz; Jordi Muntané; Adelaida Lacasta; Luís Muñoz-Bellvis; Luis González; Enara Arretxe; Cristina Alonso; Luis Bujanda; Jose J.G. Marin; Bruno Sangro; Rocio I.R. Macias
Journal of Hepatology | 2018
Ainhoa Lapitz; Ander Arbelaiz; M. Azkargorta; Marcin Krawczyk; Alvaro Santos-Laso; M.J. Perugorria; R. Jiménez-Agüero; Adelaida Lacasta; C. Ibarra; A. Sánchez-Campos; Esperanza Gonzalez; Frank Lammert; Piotr Milkiewicz; Marco Marzioni; Jose J.G. Marin; Tom H. Karlsen; J. Falcon-Perez; M. Chaparro; J. Gisbert; F. Elortza; Luis Bujanda; Jesus M. Banales
Cirugia Espanola | 2017
Yolanda Saralegui; José M. Enríquez-Navascués; Juan Pablo Ciria; Mikel Osorio; Adelaida Lacasta; Garazi Elorza; Maddi Garmendia; Carlos Placer
Cirugia Espanola | 2017
Yolanda Saralegui; José M. Enríquez-Navascués; Juan Pablo Ciria; Mikel Osorio; Adelaida Lacasta; Garazi Elorza; Maddi Garmendia; Carlos Placer
Journal of Hepatology | 2016
Maite Merino-Azpitarte; Elisa Lozano; M.J. Perugorria; Oihane Erice; Alvaro Santos-Laso; R. Jiménez-Agüero; Adelaida Lacasta; Nidhi Jalan-Sakrikar; Robert C. Huebert; Kristen M. Thelen; Sergio A. Gradilone; Ana M. Aransay; José Luis Lavin; M.G. Fernandez-Barrena; Marco Marzioni; Gregory J. Gores; Luis Bujanda; J.J.G. Marin; Jesus M. Banales